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Objectives. The objectives of this study were to analyze the
clinical and angiographic outcome of diabetic patients with suc-
cessful coronary stent placement and to compare these results
with those achieved after stenting in nondiabetic patients.
Background. The outcome of diabetic patients treated with
stent placement due to coronary artery disease has not been
assessed comprehensively.
Methods. This study analyzes a consecutive series of patients
with successful stent placement comprising 715 patients with
diabetes and 2,839 patients without diabetes. Clinical one year
follow-up and angiographic control at 6 months were part of the
protocol. Death, myocardial infarction and target lesion revascu-
larization were considered as adverse events. An automated edge
detection system was used for the angiographic assessment. The
primary clinical endpoint was event-free survival at one year. The
primary angiographic endpoint was restenosis rate at 6 months
(>250% diameter stenosis).
Results. Event-free survival was significantly lower in diabetic
than in nondiabetic patients (73.1 vs. 78.5%, p < 0.001). Survival
free of myocardial infarction was also significantly reduced in the
diabetic group (89.9 vs. 94.4% in nondiabetics, p < 0.001). The
incidence of both restenosis (37.5 vs. 28.3%, p < 0.001) and stent
vessel occlusion (5.3 vs. 3.4%, p 5 0.037) was significantly higher
in diabetic patients. Diabetes was identified as an independent
risk factor for adverse clinical events and restenosis in multivar-
iate analyses.
Conclusions. Patients with diabetes mellitus have a less favor-
able clinical outcome at one year after successful stent placement
as compared to the nondiabetic patients. The clinical follow-up
was characterized by a higher incidence of death, myocardial
infarction and reinterventions. Diabetic patients also demon-
strated an increased risk for restenosis.
(J Am Coll Cardiol 1998;32:1866–73)
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Patients with diabetes mellitus are at increased risk for the
development of coronary artery disease. Diabetes indepen-
dently worsens long-term prognosis for medically treated
patients (1–3). Aortocoronary bypass surgery (CABG), per-
cutaneous transluminal coronary angioplasty (PTCA), and
excisional atherectomy are revascularization strategies for
the treatment of patients with diabetes mellitus and coro-
nary artery disease (4 –9). In a randomized study, subgroup
analysis suggested that the long-term clinical outcome of
diabetic patients with multivessel coronary artery disease
treated with coronary artery bypass surgery is better than
when treated with coronary angioplasty (7,8); moreover,
Weintraub et al. (10) demonstrated that diabetic patients
with multivessel coronary artery disease treated with angio-
plasty have a markedly worse clinical outcome than nondi-
abetic patients. In light of these studies, even the abandon of
balloon angioplasty in diabetic patients with multivessel
coronary artery disease has been advocated (11).
Coronary stent placement is increasingly being used in a
broad range of patient populations including those with
diabetes mellitus (12). Better acute angiographic results and
prevention of adverse coronary remodeling despite the
increased neointimal hyperplasia justify the expectation of a
better outcome in diabetic patients; however, there are
conflicting reports from the studies addressing this issue.
Van Belle et al. (13) reported similar rates of restenosis and
late loss in diabetic and nondiabetic patients undergoing
coronary stenting; moreover, two other studies did not
demonstrate that diabetes represents an independent risk
factor for restenosis (14,15). In contrast, Carrozza et al. (16)
demonstrated an enhanced late loss and a higher rate of
restenosis in diabetic patients; thus, it is still unclear
whether coronary stent placement neutralizes the excess risk
that diabetic patients usually present after coronary inter-
ventions.
The objectives of this study were to analyze the clinical and
angiographic outcome of diabetic patients with successful stent
coronary placement and compare these results with those
achieved after stenting in nondiabetic patients.
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Methods
Patients. Stent placement was attempted in 3,639 patients
at our institution during the period from May 1992 through
September 1997. Excluded from this study were only patients
with unsuccessful stenting, i.e., failure to place the stent at the
desired site or to achieve a satisfactory angiographic result
(residual stenosis ,30%). There were 17 (2.3%) diabetic and
68 (2.3%) nondiabetic patients with unsuccessful stent place-
ment; thus, this study comprises 3,554 patients (715 diabetics
and 2,839 nondiabetics) with successful stent placement in
4,772 coronary lesions (991 diabetic and 3,781 nondiabetic
lesions). All were asked to undergo control angiography at 6
months or earlier in case of symptoms or objective signs of
ischemia. If the angiographic control had taken place before
the preset time and had not resulted in a reintervention at the
target lesion, the patients were encouraged to be reinvesti-
gated. Patients with any major adverse cardiac event during the
first 30 days after the procedure were not considered eligible
for the 6 month control angiography.
Stent placement and poststenting treatment. The stent
implantation technique has been described previously (17). All
patients received 15,000 units of heparin and 500 mg aspirin
intravenously prior to PTCA. Different stent types were im-
planted under fluoroscopic guidance after having been hand-
crimped on conventional angioplasty balloons. Balloon size
and pressure were at the operator’s discretion. Adequacy of
the final result was based solely on the angiographic assess-
ment.
After sheath removal and pressure bandage application,
heparin infusion was started in all patients and continued for
12 h. All patients were given orally 100 mg aspirin twice daily,
indefinitely; 16.7% of patients were treated with an anticoag-
ulation regimen comprising heparin for 5–10 days and phen-
procoumon for 4–6 weeks, and 83.3% with combined anti-
platelet therapy with ticlopidine 250 mg twice daily in addition
to aspirin (83.5% in diabetic and 83.2% in nondiabetic pa-
tients, respectively, p 5 0.831).
Coronary angiographic evaluation. Before and after the
intervention as well as at follow-up angiography, efforts were
made to control coronary vasomotion through intracoronary
nitroglycerin administration. Qualitative angiographic assess-
ment was done by the operator during or immediately after the
procedure. The angiogram was assessed for the presence of
vessel occlusion before PTCA or stenting and dissections
immediately before stent placement. Lesions were classified
using the modified American College of Cardiology/American
Heart Association grading system (18). Complex lesions were
considered lesions of type B2 and C. Reduced left ventricular
function was considered when the ejection fraction was equal
to or less than 50%. Quantitative angiographic analysis was
made by operators unaware of the clinical characteristics of the
patients using the automated edge detection system CMS
(Medis Medical Imaging Systems, Nuenen, The Netherlands).
The contrast-filled nontapered catheter tip was used for cali-
bration. The measurements were done on the angiogram
before and immediately after stenting, and on that recorded at
follow-up. The parameters obtained were minimal lumen
diameter (MLD), reference diameter (RD), diameter stenosis
and diameter of the maximally inflated balloon. The proce-
dural and technical details of the quantitative analysis using
CMS have been described elsewhere (19). Acute gain was
calculated as the difference between MLD immediately after
the procedure and MLD before the intervention; late lumen
loss was calculated as the difference between MLD immedi-
ately after the procedure and MLD at follow-up. Loss index
was calculated as the ratio of late lumen loss and acute gain.
Restenosis was defined as a diameter stenosis $50% at control
angiography.
Definitions and outcome measures. The study population
was divided into two groups according to the presence or
absence of diabetes mellitus. Patients were classified as having
diabetes if it was documented on medical reports, if they were
taking insulin or oral hypoglycemic agents, or on the basis of
elevated levels (.140 mg dl21) of fasting, nonstressed blood
glucose on at least two separate occasions during the hospital
stay corresponding to the stent placement procedure. In
addition, diabetic patients were classified into three subgroups
according to the antidiabetic regimen at the time of the initial
intervention (insulin, oral hypoglycemic drugs or diet alone).
Major adverse cardiovascular events (MACE) were defined as
death of any cause, nonfatal myocardial infarction and target
lesion revascularization (CABG or repeat PTCA of the stented
lesion). All deaths were considered of cardiac origin unless a
noncardiac etiology was established by autopsy. The diagnosis
of acute myocardial infarction was established in the presence
of a clinical episode of prolonged chest pain and a rise in serum
cardiac enzyme levels to at least twice the upper normal limit,
or the appearance of one or more new pathologic Q waves.
Cardiac events were monitored throughout the follow-up
period. The assessment was made on the basis of the informa-
tion provided by hospital readmission records, referring phy-
sician or phone contact. For all those patients who revealed
cardiac symptoms during phone contact, at least a clinical and
electrocardiographic check-up was performed at the outpa-
tient clinic or by the referring physician. The diagnosis of stent
vessel occlusion was always based on symptom-driven or
routinely scheduled coronary angiography in the presence of
Thrombolysis in Myocardial Infarction (TIMI) flow grade 0 or
1. The restenosis rate and late lumen loss were used as
angiographic measures of restenosis.
Statistical analysis. The analyses were made on a per-
patient basis, selecting randomly only one lesion in patients
Abbreviations and Acronyms
CABG 5 aortocoronary bypass surgery
CART 5 classification and regression tree
MACE 5 major adverse cardiovascular events
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with multilesion interventions; moreover, for primary end-
points (both clinical and angiographic), this approach was
validated through a repeated analysis confined separately to
patients with single- and multivessel coronary disease. The
discrete variables were expressed as counts and compared with
Fisher’s exact test. Continuous variables were expressed as
mean 6 SD and unpaired, two-tailed t test was used for two
group comparisons and analysis of variance for comparisons
between more than two groups. Event-free survival curves for
all cardiac events and specifically for recurrent myocardial
infarction were constructed by means of the Kaplan-Meier
method. Survival probabilities of the two groups were com-
pared with the log-rank test. Multivariate models (20) were
used to test for the potential independent role of diabetes on
restenosis (logistic regression) and clinical outcome (Cox
proportional hazards regression). In addition to the presence
or absence of diabetes, several other clinical, angiographic and
procedural variables were entered into the models. The list of
these factors comprised age, sex, smoking, hypertension, hy-
percholesterolemia, multivessel disease, reduced left ventricu-
lar function, unstable angina, acute myocardial infarction,
vessel size, stenosis length, MLD before and immediately after
the intervention, balloon pressure, balloon to vessel ratio,
number and type of stents, presence of residual dissection,
stent overlap and thrombus after stenting. We verified for each
Cox model whether diabetes violated the proportional hazards
assumption. This assumption failed only for the event-free
survival model, and thus, the necessary correction was made
adding diabetes as a time-dependent covariable in the model
(20). We used the Cox models for the calculation of the
adjusted survival rates and the logistic regression model for the
calculation of the adjusted restenosis rates in diabetic and
nondiabetic patients (20). Patient- and lesion-related charac-
teristics of the patients with diabetes were also analyzed with
the classification and regression tree (CART), and further
stratification in subgroups with different risk for restenosis
were obtained. Statistical evaluation was performed with
S-Plus statistical software, version 4.0 Professional (MathSoft,
Inc) extended with a special library (20). P-values less than 0.05
were considered statistically significant.
Results
Baseline characteristics. Of 715 diabetic patients, 220 were
on insulin, 223 on oral hypoglycemic therapy and 272 on diet
alone. Table 1 displays the results of the analysis of the
baseline clinical characteristics. It shows that patients with
diabetes were older, with a greater proportion of women and a
less frequent habit of smoking; more often they had arterial
hypertension and previous documented myocardial infarction
and a lower incidence of acute myocardial infarction. Reduced
left ventricular function and multivessel coronary disease were
also more frequently present in diabetic patients. Table 2
shows the angiographic and procedural characteristics. Dia-
betic patients had a smaller vessel size, and accordingly, a
smaller MLD immediately after stent placement. The patients
also showed differences in the types of stent used.
Clinical outcome. There were significant differences in the
frequency of adverse cardiovascular events between the two
groups during the first 30 days (Table 3). The incidence of any
MACE during this period was 6.7% in the diabetic and 3.8% in
the nondiabetic patients. The incidence of death and repeat
PTCA was significantly higher in diabetics compared to non-
diabetics. In addition, there was a clear trend to a higher
incidence of myocardial infarction and subacute stent throm-
bosis in diabetics.
After one year, the probability of survival was significantly
lower in diabetic patients (91.7 vs. 96.2%, p , 0.001) as was the
probability of survival free of myocardial infarction (89.9 vs.
94.4%, p , 0.001, Fig. 1). The cardiac mortality rate was 5.7%
in diabetic and 2.9% in nondiabetic patients (p , 0.001). The
incidence of the composite endpoint of cardiac death and
nonfatal myocardial infarction was significantly higher in dia-
betic patients (8.0 vs. 4.6%, p , 0.001). The probability of
event-free survival was significantly lower in diabetic as com-
pared to nondiabetic patients (73.1 vs. 78.8%, p , 0.001, Fig.
2). Repeat PTCA was performed more frequently in diabetics
than in nondiabetic patients (21.1 vs. 15.6%, p , 0.001) while
the rate of CABG was similar in both groups (2.4 vs. 2.3%).
Nontarget lesion revascularizations were performed in 7.3% of
the diabetic and 7.5% of the nondiabetic patients (p 5 0.810).
Significant differences in event-free survival between the two
groups were also recorded when the analysis was confined to
patients with single-vessel (74.3 vs. 81.6%, p 5 0.029) and
multivessel coronary artery disease (72.7 vs. 77.0%, p 5 0.02).
The probability of survival remained significantly lower in
diabetics as compared to nondiabetics even after adjustment
for the confounding role of other factors (96.2 vs. 98.2%, p ,
0.001). Similarly, both the adjusted probability of survival free
of myocardial infarction (93.4 vs. 96.0%, p , 0.001) and the
adjusted event-free survival (76.6% vs. 81.3%, p 5 0.003) were
significantly reduced in diabetic patients.






(n 5 2,839) p
Women 31.9 20.9 , 0.001
Age (yrs) 66.7 6 9.6 62.5 6 10.9 , 0.001
Cigarette smoking 23.8 35.5 , 0.001
Hypercholesterolemia 39.0 37.1 0.332
Arterial hypertension 75.0 63.0 0.011
Unstable angina 32.4 31.0 0.466
Acute myocardial infarction 15.8 19.6 0.021
Previous myocardial infarction 32.7 28.0 0.013
Reduced left ventricular function 26.3 19.2 , 0.001
Previous PTCA 25.2 23.6 0.367
Previous CABG 12.0 11.6 0.724
Multivessel intervention 28.0 25.7 0.219
Multivessel disease 77.1 66.5 , 0.001
Data are mean 6 SD or percentages; CABG 5 aortocoronary bypass
surgery; PTCA 5 percutaneous transluminal coronary angioplasty.
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Diabetic patients receiving insulin had a trend to a lower
event-free survival as compared to diabetic patients receiving
hypoglycemic therapy or diet alone (70.2% vs. 73.2% vs.
75.5%, respectively; p 5 0.15).
Results of follow-up angiography. In eligible patients, an-
giographic follow-up at 6 months was performed in 79.0 and
81.6% in the diabetic and nondiabetic group, respectively (p 5
0.110). Angiographic data at follow-up are shown in Table 4.
Patients with diabetes had a smaller MLD and greater diam-
eter stenosis at follow-up. There was a greater late lumen loss,
and loss index in diabetic patients. Diabetic patients showed a
significantly higher restenosis rate than nondiabetic patients
(37.5 vs. 28.3%, p , 0.001). They also had a higher incidence
of late total occlusions which was not dependent on the type of
poststenting therapy (4.6% in patients with anticoagulation
and 5.5% in those with ticlopidine). The restenosis rate
remained significantly higher in the subgroup of lesions that
were not totally occluded at follow-up angiography (32.2 vs.
25.9%, p , 0.001). The same was also true for late lumen loss
(1.19 6 0.78 vs. 1.04 6 0.74 mm, p , 0.001). Differences in the
restenosis rate between the two groups also remained signifi-
cant when the analysis was restricted to only patients with
single-vessel disease (35.6 and 26.9% in diabetic and nondia-
betic group, respectively; p , 0.001) or multivessel disease
(43.4 and 29.0%, p , 0.001). In addition, the restenosis rate
was higher in diabetics compared to nondiabetics both for
large ($3 mm) vessels (29.5 vs. 21.2%, p 5 0.003) and for small
vessels (46.3 vs. 37.1%, p 5 0.008); a significant difference was
also present when the analysis was confined to single-stent
lesions (33.4 vs. 24.1%, p , 0.001) or multiple-stent lesions
(42.8 vs. 34.2%, p 5 0.015). Diabetic patients also had a higher
restenosis rate in native vessels (38.4 vs. 28.4%, p , 0.001).






(n 5 2,839) p
Vessel
Left main artery 1.3 1.7 0.893
Left anterior descending artery 38.7 42.4 0.301
Circumflex artery 17.3 18.5 0.722
Right coronary artery 35.8 31.8 0.241
Saphenous vein graft 6.8 5.6 0.744
Restenotic lesions 14.9 13.2 0.805
Complex lesions 73.0 72.5 0.782
Dissection before stenting 46.2 45.6 0.887
Stenosis length (mm) 10.7 6 5.6 11.0 6 5.8 0.163
Vessel size (mm) 3.03 6 0.52 3.07 6 0.53 0.060
MLD before intervention (mm) 0.71 6 0.50 0.71 6 0.50 0.783
MLD after intervention (mm) 2.91 6 0.50 2.95 6 0.50 0.044
Balloon pressure (atm) 13.7 6 3.3 13.8 6 3.2 0.496
Balloon to vessel ratio 1.04 6 0.11 1.04 6 0.12 0.680
Acute gain (mm) 2.20 6 0.64 2.24 6 0.63 0.196
Multistent placement 43.5 41.8 0.414
Stented segment length (mm) 18.9 6 12.5 18.5 6 11.3 0.423
Palmaz-Schatz stent 43.4 47.0 0.082
Inflow stent 28.1 24.2 0.031
PURA-A stent 13.3 13.8 0.717
NIR stent 10.1 8.0 0.080
Other type of stent 5.2 7.0 0.084
Stent overlap 20.3 19.6 0.676
Thrombus after stenting 7.6 7.7 0.909
Residual dissection after stenting 2.1 2.7 0.355
Diameter stenosis before intervention (%) 76.6 6 15.6 76.7 6 15.6 0.858
Diameter stenosis after intervention (%) 5.4 6 8.8 5.4 6 9.2 0.904
Data are mean 6 SD or percentages; MLD 5 minimal lumen diameter.







(n 5 2,839) p
Early MACE 6.7 3.8 , 0.001
Cardiac death 2.7 1.4 0.019
Nonfatal myocardial infarction 2.1 1.2 0.079
CABG 0.1 0.3 0.499
PTCA 3.9 2.3 0.018
Subacute stent occlusion 3.2 2.0 0.060
Data are percentages; CABG 5 aortocoronary bypass surgery; PTCA 5
percutaneous transluminal coronary angioplasty; MACE 5 major adverse car-
diac events.
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The adjusted probability of restenosis was 35.9% in diabetics
and 27.6% in nondiabetics (p , 0.001).
Angiographic outcome within the diabetic group according
to the therapeutic regimen is shown in Table 5. There were no
significant differences between the subgroups in terms of
restenosis rate and late lumen loss.
Fig. 3 displays the interaction between diabetes and vessel
size (obtained from the multivariate logistic model) on the
probability of restenosis. It can be noted that a higher risk for
restenosis is expected for diabetics throughout the vessel size
range. The results of CART analysis demonstrate that patients
with diabetes can be further subdivided into subgroups with
different risk for restenosis. Complex lesions situated in small
vessels (,3 mm) have a particularly high risk of restenosis
(49.1%). On the other extreme, simple lesions in large vessels
have a considerably lower risk of restenosis (27.3%).
Discussion
The main findings of the present study indicate that patients
with diabetes mellitus have a less favorable clinical outcome at
one year after successful stent placement. In addition, there
was a higher incidence of angiographic restenosis and stent
occlusion at 6 months. Adverse events such as death, myocar-
dial infarction and target lesion revascularization occurred
more frequently in diabetic than in nondiabetic patients. Even
after adjusting for concomitant clinical and angiographic char-
acteristics, diabetes mellitus remained as an independent risk
factor for a worse angiographic and clinical outcome.
Clinical outcome. Analysis of baseline clinical characteris-
tics revealed that cardiovascular risk factors were more prev-
alent in diabetic patients. Diabetics were older, more often
female, with a higher prevalence of hypertension, previous
myocardial infarction and reduced left ventricular function. On
the basis of these differences, a worse clinical outcome in this
group of patients could be expected. Indeed in the first 30 days,
there was a significant difference in the incidence of MACE
and subacute stent closure between the two groups. There
were more cardiac deaths and repeat PTCAs; moreover, there
was a clear trend to a higher incidence of nonfatal myocardial
infarction among diabetic patients.
One year clinical follow-up in our study population reveals
Figure 1. Survival curves for freedom from myocardial
infarction for diabetic and nondiabetic patients.
Figure 2. Event-free survival curves for diabetic and
nondiabetic patients. Death, myocardial infarction and
target lesion revascularization were considered as ad-
verse events.
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that patients with diabetes have a lower probability of survival
free of myocardial infarction compared to nondiabetic pa-
tients; moreover, the overall clinical outcome was worse in the
diabetic group due also to a higher frequency of target lesion
revascularizations. Most of the difference in risk was achieved
within the first 6 months after the intervention. This corre-
sponds to the period in which most of the lumen renarrowing
after stent implantation occurs (21) and the increased inci-
dence of restenosis in diabetics may explain this risk pattern.
We did not find a significant influence of gender or type of
antidiabetic management on the clinical outcome of diabetic
patients. The results of univariate analysis were confirmed by
the Cox proportional hazards regression model which identi-
fied diabetes as an independent risk factor for major adverse
cardiac events during one year follow-up. These results are in
agreement with a previous report by Laham et al. (22) who
found diabetes mellitus to be an independent predictor of
adverse clinical events.
Angiographic outcome. The restenosis rate was higher in
patients with diabetes. This explains the more frequent need
for target vessel revascularization in this group. This higher
rate of angiographic restenosis was not solely due to the higher
reocclusion rate because the restenosis rate remained signifi-
cantly higher even after lesions with total occlusion at
follow-up were excluded. This is in contrast with a previous
report (13) that compared 56 diabetic with 244 nondiabetic
patients, and found no significant difference in restenosis rate
after stent placement. Two other studies comprising a small
number of patients with diabetes (40 and 7 patients, respec-
tively) failed to demonstrate a significant independent influ-
ence of diabetes mellitus on the restenosis process (14,15);
however, the power to detect a significant difference may have
been insufficient considering their limited number of patients
with diabetes. Differences in inclusion criteria and baseline
characteristics may also account for the lower restenosis rates
reported previously (13); however, our data demonstrated that
even in large vessels or in lesions with single-stent placement,
as was the case in 80% of the patients studied in the report of
Van Belle et al. (13), restenosis remained significantly higher
in diabetics as compared to nondiabetics. Our study concurs
with a previous report that also found a higher restenosis rate
after stenting in diabetic patients (16).
Among patients with diabetes, we could not demonstrate
any significant impact of therapeutic regimen on the angio-
graphic and clinical outcome; however, this subgroup analysis
may be underpowered to detect a significant difference. These
results should therefore be interpreted with caution.
Stratification analysis using CART showed that more unfa-
vorable results are expected for patients with complex lesions
located in small vessels whereas the restenosis rate corre-
sponding to simple lesions situated in large vessels is not
different from that reported for BENESTENT- and STRESS-
lesions (23,24) despite the presence of diabetes.
There are a number of mechanisms able to explain the
higher restenosis and occlusion rate in diabetic patients.
Diabetics have a number of hematological abnormalities that
can predispose them for an enhanced risk of vascular throm-
bosis. Spontaneous and induced platelet aggregation is in-
creased (25,26), platelet synthesis of thromboxane A2 is en-
hanced (25) and platelet activation (platelet factor 4 and
b-thromboglobulin) can be elevated (26). In addition, a rela-
tively greater coagulation activity (27) may be present in
diabetic patients. Procoagulant factors, (fibrinogen, factor VII,
and von Willebrand factor) may be increased in diabetics (26).
Mechanisms involved in reducing intravascular clotting may
also be impaired. Synthesis of prostacyclin is reduced (26), and
fibrinolysis may be attenuated because of increases in plasmin-
ogen activator inhibitor type 1 (26,28). In addition, a number
of functional abnormalities of the vascular endothelium are
associated with diabetes mellitus that may further pronounce
the propensity to vasospasm and coronary thrombosis. Hyper-






(n 5 2,230) p
MLD (mm) 1.64 6 0.89 1.86 6 0.89 , 0.001
Late loss (mm) 1.27 6 0.84 1.10 6 0.80 , 0.001
Loss index 0.61 6 0.43 0.52 6 0.40 , 0.001
Diameter stenosis (%) 46.1 6 26.8 39.9 6 25.8 , 0.001
Restenosis rate 37.5 28.3 , 0.001
-Total occlusions 5.3 3.4 0.037
-Stenoses 32.2 25.9 , 0.001
Data are mean 6 SD or percentages; MLD 5 minimal lumen diameter.







(n 5 192) p
MLD (mm) 1.58 6 0.93 1.58 6 0.89 1.74 6 0.86 0.078
Late loss (mm) 1.22 6 0.84 1.34 6 0.82 1.24 6 0.86 0.879
Loss index 0.62 6 0.47 0.64 6 0.43 0.57 6 0.41 0.241
Diameter stenosis (%) 46.1 6 28.9 48.2 6 26.0 44.2 6 25.4 0.470
Restenosis rate 40.5 38.9 33.9 0.399
-Total occlusions 7.4 5.9 3.1 0.194
-Stenoses 33.1 33.0 30.8 0.701
Data are mean 6 SD or percentages; MLD 5 minimal lumen diameter.
1871JACC Vol. 32, No. 7 ELEZI ET AL.
December 1998:1866–73 CORONARY STENTING IN DIABETIC PATIENTS
glycemia directly causes endothelial dysfunction by decreasing
the production of endothelium-derived relaxing factor (29),
increasing oxidative stress (30) by vascular protein glycation
(30) and free radical formation (31), and decreasing prostacy-
clin production (32). Also, lipoprotein abnormalities (33) may
impair endothelium-dependent relaxation (34); moreover, a
greater growth factor stimulation occurs in diabetics (30,35).
All these mechanisms may also lead to a pronounced intimal
hyperplasia, the main mechanism of restenosis in diabetic
patients (36).
Two major clinical implications may derive from our find-
ings. Firstly, diabetes is often associated with other risk factors
that may influence the outcome; accordingly, the decision to
intervene with a certain revascularization technique would
heavily depend on a thorough clinical and angiographic assess-
ment. Secondly, diabetic patients will have a worse outcome
independently from the presence or absence of other clinical
and angiographic risk factors. Since other studies have also
demonstrated a less favorable outcome of diabetic patients
after either CABG or PTCA (8,10), better medical treatment
of diabetes (35) by controlling more vigorously the hypergly-
cemic state may be of crucial importance for the reduction of
the excessive risk of these patients.
Study limitations. The main limitation of this study is that
no other revascularization strategy except for stenting was
evaluated in diabetic patients. Prospective, randomized studies
comparing stenting with CABG or PTCA are warranted in
diabetic patients. The requirement for insulin was based on the
mode of treatment of the patient at admission and not on a
careful study of whether the patient had type I or type II
diabetes mellitus. In addition, the adequacy of glycemic control
was not available; thus, a specific analysis of the relation
between glycemic control and long-term outcome could not be
performed. The lack of intravascular ultrasound assessment
must be considered an additional limitation of the present
study. It might have provided more insights into potential
specific restenosis mechanisms present in lesions of diabetic
patients; however, there are careful studies addressing this
issue (36). Another limitation of the study may derive from the
incomplete angiographic follow-up. This is unlikely to have
biased in a significant manner our results because of two
reasons. Firstly, the relatively small proportion of patients
without angiographic restudy (,20%) had one-year clinical
follow-up which minimizes the likelihood of missing major
adverse events. Secondly, Kuntz et al. (37) have demonstrated
that the potential selection bias is reduced for angiographic
follow-up rates similar to that recorded in the present study.
Nonrestudied patients are more likely to be asymptomatic
(37). It is highly improbable that diabetic asymptomatic pa-
tients without control angiography might have a lower inci-
dence of restenosis than their nondiabetic counterparts.
Conclusions. Patients with diabetes mellitus have a less
favorable clinical outcome at one year after successful stent
placement. All adverse outcome measures such as death,
myocardial infarction and target lesion revascularization oc-
curred more frequently in diabetic than nondiabetic patients.
In addition, there was a higher frequency of angiographic
restenosis and stent vessel occlusion. Patients with diabetes
have a higher prevalence of other cardiovascular risk factors;
however, our findings indicate that diabetes is an independent
risk factor for a worse angiographic and clinical outcome.
Coronary stent placement thus does not appear to eliminate
the excessive cardiovascular risk that diabetic patients present
after coronary interventions.
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